SCHEMBL4478052

SCHEMBL4478052

OCc1cc(Br)ccc1OCCN1CCCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
PTGDR2 Q9Y5Y4 1/20 0.51
LTA4H P09960 1/20 0.51
PTGS2 P35354 1/20 0.51
ALDH1A1 P00352 2/20 0.51
HTR1B P28222 1/20 0.51
KDM4E B2RXH2 4/20 0.49
TDP1 Q9NUW8 2/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
CCR5 P51681 1/20 0.48
HRH1 P35367 3/20 0.48
DRD1 P21728 2/20 0.48
DRD4 P21917 2/20 0.48
DRD5 P21918 2/20 0.48
DRD3 P35462 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4484633 0.86 MEN1 (0.57) MEN1KMT2ALTA4HPTGS2ALDH1A1
SCHEMBL4481567 0.86 MEN1 (0.57) MEN1KMT2ALTA4HPTGS2ALDH1A1
SCHEMBL2322967 0.82 HTR1B (0.67) MEN1KMT2ALTA4HPTGS2ALDH1A1
SCHEMBL6593991 0.79 MEN1 (0.85) MEN1KMT2ALTA4HPTGS2ALDH1A1
SCHEMBL2329109 0.79 ALDH1A1 (0.67) MEN1KMT2ALTA4HPTGS2ALDH1A1
SCHEMBL2322184 0.79 LTA4H (0.61) MEN1KMT2ALTA4HPTGS2ALDH1A1
SCHEMBL2323789 0.78 LTA4H (0.66) MEN1KMT2ALTA4HPTGS2ALDH1A1
SCHEMBL227430 0.78 LTA4H (0.60) MEN1KMT2ALTA4HPTGS2ALDH1A1
SCHEMBL226018 0.78 LTA4H (0.60) MEN1KMT2ALTA4HPTGS2ALDH1A1
SCHEMBL7772243 0.78 HRH1 (0.56) MEN1KMT2ALTA4HHTTCCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592358-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-22 US disclosed
EP-1737823-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2007-01-03 EP disclosed
WO-2005103002-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO disclosed
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US disclosed
US-6265575-B1 THROMBIN INHIBITORS ELI LILLY AND COMPANY 2001-07-24 US disclosed
US-6251921-B1 ADMINISTERING THROMBIN INHIBITING DIAMINE COMPOUND TO MAMMAL ELI LILLY AND COMPANY 2001-06-26 US disclosed
US-6025382-A Antithrombotic diamines ELI LILLY AND COMPANY (US) 2000-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 MEN1 1312/4885KMT2A 1176/4885PTGDR2 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.